InMed expands Phase II cannabinol trial to include adolescents

InMed Pharmaceuticals has expanded its Phase II trial of INM-755, a cannabinol cream, to include adolescents.

The trial is designed to enroll up to 20 patients with all four types of inherited EB – dystrophic EB, EB Simplex, Junctional EB and Kindler Syndrome – and will run across multiple sites in seven countries.

After analysis of the first five adult patients to complete the trial, an independent Data Monitoring Committee agreed it is safe to allow the enrollment of children aged between 12 and 17. The first adolescent patient has been enrolled and completed the 28-day treatment period. To date, nine patients have been enrolled so far.

For more information, read the InMed press release.